… ProQR Announces CTA Submission for Phase 1 Study of AX-0810 … first submitted Clinical Trial Application (CTA) advancing ProQR’s Axiomer™ ADAR-mediated RNA editing platform into … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through …
… ProQR Announces Webcast of Presentation at the Upcoming … Netherlands & CAMBRIDGE, Mass., November 3, 2022 -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … will be accessible from the “Investors & Media” section of ProQR’s website ( https://www.proqr.com/ ) under “ Events ”. …
… ProQR to Participate in the LifeSci 2nd Annual Genetic … & CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … will be accessible from the “Investors & Media” section of ProQR’s website ( https://www.proqr.com/ ) under “ Events ”. …
… ProQR Announces Strategic Changes to the Management Team and … said Daniel A. de Boer, chief executive officer of ProQR. “As we are moving into late stage development we are … reporting to David Rodman, MD, Executive Vice President of R&D. Aniz is an experienced ophthalmologist and has over 20 …
… ProQR Announces Webcast of Presentation at Upcoming HC … will be accessible from the “Investors & Media” section of ProQR’s website ( www.proqr.com ) under “ Events ” for approximately 30 days …
… ProQR Therapeutics Announces Results for the Fourth Quarter … said Daniel de Boer, Chief Executive Officer of ProQR. "We have advanced QR-010 through preclinical … the Company's IPO on the Nasdaq Global Market, a grant to ProQR's protection foundation, and increased costs reflecting …
… ProQR Appoints John Maraganore, PhD, as Strategic Advisor to … & CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … if any,” said Daniel A. de Boer, Founder and CEO of ProQR. “As the founding CEO of Alnylam, he built and led one …